Home E-Weekly December 19, 2017

FDA Reaffirms Advice Against Use of Morcellators to Treat Uterine Fibroids

Published: December 18, 2017

STILL A DANGER The FDA reviewed case studies that showed morcellators could be associated with spreading cancerous tissue.

The FDA last week reaffirmed an earlier warning that the use of laparoscopic power morcellators to treat uterine fibroids in women with unsuspected uterine sarcoma can spread the cancerous tissue within the abdomen and pelvis.

The FDA first cautioned against the use of laparoscopic power morcellators during hysterectomy or myomectomy for uterine fibroids in a 2014 safety communication.

"Since the FDA first issued warnings about the risk of spreading unsuspected uterine cancer from the use of laparoscopic power morcellators, we have continued to review new research to ensure our recommendations reflect the most current scientific evidence. Our latest analysis found a similar incidence of these hidden cancers to our estimate 3 years ago," says Jeff Shuren, MD, director of the FDA's Center for Devices and Radiological Health, in statement.

Anna Merriman

New to Outpatient Surgery Magazine?
Sign-up to continue reading this article.
Register Now
Have an account? Please log in:
Email Address:
  Remember my login on this computer

advertiser banner

Other Articles That May Interest You

Florida Nurse Arrested for Stealing Fentanyl

News & Notes

AORN Acquires Outpatient Surgery Magazine